Zusammenfassung
Die PET/CT kann als die derzeit umfassendste Untersuchungsmethode in der Onkologie angesehen werden. Sie vereint eine praxistaugliche Untersuchungstechnik für den Ganzkörper, betont die Stärken nuklearmedizinischer Diagnostik und verknüpft diese mit radiologischen Domänen. In Zeiten knapper Ressourcen wird es darauf ankommen, diagnostische Leitpfade, Qualitätszertifizierungen und Mengenbegrenzungsstrategien zu entwickeln, die eine möglichst frühzeitige und therapierelevante Nutzung der PET(/CT) gestatten.
Abstract
PET/CT has been established as the most comprehensive imaging modality in oncology. This innovative method combines simplified examinations techniques for whole body imaging, emphasizes the strength of nuclear medicine and combines these with radiological procedures. Further development of these combined imaging modalities requires to develop integrated diagnostic pathways, instruments of quality control and strategies to limit the number of examinations in order to assure the earliest and therapy relevant use of PET(/CT).
Schlüsselwörter
Key words
Literatur
-
1 Bundesministerium für Gesundheit .Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses nach § 91 Abs. 7 des Fünften Buches Sozialgesetzbuch (SGB V) zur Positronenemissionstomographie. BAnz. 2.3.2006; 43: 1374
-
2 DTZ Berlin .„PET/CT als therapiesteuerndes Instrument in der onkologischen Diagnostik”. In: Mohnike W (Hrsg). 4. Berliner PET/CT-Symposium 2006
-
3 PET e. V .„PET/CT zwischen Innovationsförderung und Mengenproblem”. Protokoll zum Petersberger Gespräch zum Aspekt der Innovationsimplementierung. www.bdn-online.de 2006
-
4
Bengel F M.
Is the future of nuclear medicine written in the genes?.
Eur J Nucl Med Mol Imaging.
2004;
31
309-311
-
5
Bengel F M.
Noninvasive imaging of cardiac gene expression and its future implications for molecular therapy (Review Article).
Mol Imaging Biol.
2005;
7
22-29
-
6
Bengel F M, Anton M, Richter T. et al .
Noninvasive imaging of transgene expression by use of positron emission tomography in a pig model of myocardial gene transfer.
Circulation.
2003;
108
2127-2133
-
7
Cohade C, Osman M, Leal J, Wahl R L.
Direct comparison of 18F-FDG PET and PET/CT in patients with colorectal carcinoma.
J Nucl Med.
2003;
44
1797-1803
-
8
Dietlein M, Schicha H.
Vergütung der PET bei onkologischen Fragestellungen in Europa: eine Umfrage.
Nuklearmedizin.
2003;
42
80-85
-
9
Freudenberg L S, Antoch G, Schütt P. et al .
FDG-PET/CT in restaging of patients with lymphoma.
Eur J Nucl Med Molec Imaging.
2004;
31
325-329
-
10
Herholz K, Nordberg A, Salmon E. et al .
Metabolic impairment of associations cortex predicts progression in Alzheimer's disease: a prospective multicenter positron emission tomography study (PET).
Eur J Neurol.
1998;
5
S24
-
11
Herholz K, Schopphoff H, Schmidt M. et al .
Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease.
J Nucl Med.
2002;
43
21-26
-
12
Hoskin P J.
PET in lymphoma:what are the oncologists needs?.
Eur J Nucl Med.
2003;
30 (Suppl 1)
S37-S41
-
13
Juweid M E, Wiseman G, Mendal Y. et al .
Integrated positron emission tomography/computed tomography-based response classification for non-Hodgkin's lymphoma (Abstr. No. 66).
Molecular Imaging and Biology.
2004;
6
86
-
14
Kaufmann P A.
Die zukünftige Rolle von PET in der Kardiologie.
Der Nuklearmediziner.
2004;
27
208-212
-
15
Körholz D, Kluge R, Wickmann L. et al .
Importance of F-18 fluorodeoxy D-2 glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence - consequences for the GHPOH-HD 2003 protocol.
Onkologie.
2003;
26
489-493
-
16
Krause B J, Blumstein N M, Schäfer S. et al .
Evaluation of F-18-FDG PET/CT in patients suspected of local recurrence of colorectal cancer introduced to external conformal radiotherapy.
Eur J Nucl Med Mol Imaging.
2004;
31
S285
-
17 Mohnike W, Hör G. PET/CT-Atlas. Springer, Berlin, Heidelberg 2006
-
18
Namdar M, Hany T F, Burger C. et al .
Combined computed tomography-angiogram and positron emission tomography perfusion imaging for assessment of coronary artery disease in a novel PET/CT: A pilot feasibility study.
J Am Coll Cardiol.
2003;
41 (Suppl A)
439A
-
19
Namdar M, Hany T F, Koepfli P. et al .
Integrated PET/CT for the assessment of coronary artery disease: A feasibility study.
J Nucl Med.
2005;
46
930-935
-
20 Oberender P. Kosten-Nutzen-Analyse der PET- und PET/CT-Diagnostik am Beispiel des nicht-kleinzelligen Bronchialkarzinoms (NSCLC). Diagn. Therapeut. Zentrum/BDN 2004
-
21
Osman M M, Cohade C H, Fishman E F, Wahl R.
Clinically significant incidental findings on the unenhanced CT portion of PET/CT studies: Frequency in 250 patients.
J Nucl Med.
2005;
46
1352-1355
-
22
Schlag P, Lehner B, Strauss L G, Georgi P, Herfarth C H.
Scar or recurrent rectal cancer (Positron emission tomography is more helpful for diagnosis than immunoscintigraphy).
Arch Surg.
1989;
124
197-200
-
23
Schroeder F.
The European randomized study of screening prostate cancer (ERSCP).
Br J Radiol.
1997;
79
68-71
-
24
Townsend D W.
PET/CT today and tomorrow.
JNM.
2004;
45
4S-14S
-
25
van Tinteren H, Hoekstra O S, Smit E F. et al .
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non small cell lung cancer: The PLUS multicentre randomized trial.
Lancet.
2002;
359
1388-1392
-
26
Schulthess G K von.
Maximizing the benefit of integrated PET/CT: the road ahead.
Eur J Nucl Med Mol Imaging.
2004;
31
1462-1463
-
27
Wahl R.
Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT.
JNM.
2004;
45
82S-95S
Prof. Dr. med. em. G. Hör
Diagnostisch-Therapeutisches Zentrum (DTZ) Berlin
Kadiner Str. 23
10243 Berlin
Phone: +49/30/5 59 68 61
Email: nuklearmedizin@berlin-diagnostik.de
